This is a weird comment. We focus on suicidal thoughts because suicidal thoughts are scary to people in a way that vomiting or a rash or blurred vision is not, because the former makes people consider a potentially life ending outcome, while the latter do not. Whether or not you agree with the relative ranking of these concerns, it ought to be easy to understand why.

And the rate of suicidal ideation per reported adverse event is irrelevant as something to compare unless you've also confirmed that the rate of adverse event reports is comparable between the two drugs. Have you? If so, why are you citing the rate per adverse event case rather than the rate relative to number of users, or doses?

Even so, even if they are in fact comparable, we're focusing on these drugs because they're fairly new and have seen an explosive increase in use, just like we've focused on other drugs when they've seen the same explosive increase in use. That people are extra interested in any potentially serious effects of a fairly new drug should not be surprising at all. Why does it surprise you?